

Dan Granberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4719707/publications.pdf>

Version: 2024-02-01

20
papers

1,376
citations

623734

14
h-index

794594

19
g-index

26
all docs

26
docs citations

26
times ranked

1655
citing authors

#	ARTICLE	IF	CITATIONS
1	Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2986-2991.	7.0	438
2	Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2015, 56, 177-182.	5.0	179
3	Prospective observational study of ¹⁷⁷ Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 970-988.	6.4	179
4	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	3.1	114
5	Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. <i>Journal of Global Oncology</i> , 2017, 3, 43-53.	0.5	105
6	Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids. <i>Neuroendocrinology</i> , 2013, 98, 151-155.	2.5	79
7	Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷ Lu-DOTATATE. <i>Cancers</i> , 2019, 11, 909.	3.7	56
8	Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1425-1431.	6.4	47
9	Metastatic Pheochromocytomas and Abdominal Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1937-e1952.	3.6	41
10	Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours. <i>PLoS ONE</i> , 2014, 9, e86756.	2.5	32
11	¹⁷⁷ Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. <i>Neuroendocrinology</i> , 2021, 111, 330-343.	2.5	31
12	Kidney dosimetry during ¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. <i>Acta Oncologica</i> , 2018, 57, 516-521.	1.8	24
13	Regression of a Large Malignant Gastrinoma on Treatment with Sandostatin LAR [®] : A Case Report. <i>Digestion</i> , 2008, 77, 92-95.	2.3	23
14	Biochemical Testing in Patients with Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , 2015, 44, 24-39.	1.0	14
15	A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of ¹⁷⁷ Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma—“LuDO-N. <i>Frontiers in Pediatrics</i> , 2022, 10, 836230.	1.9	5
16	EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study. <i>Journal of Clinical Oncology</i> , 2022, 40, 4596-4596.	1.6	4
17	Treatment of Liver Metastases in Patients with Neuroendocrine Tumors. <i>International Journal of Hepatology</i> , 2012, 2012, 1-2.	1.1	3
18	Bronchial carcinoids. <i>International Journal of Endocrine Oncology</i> , 2019, 6, IJE16.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Lung neuroendocrine tumor (NET) patient (pt)-reported experience: Results from the first global NET pt survey—A collaboration between the international neuroendocrine cancer alliance (INCA) and Novartis pharmaceuticals.. Journal of Clinical Oncology, 2015, 33, e17739-e17739.	1.6	1
20	Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study. International Journal of Endocrine Oncology, 2017, 4, 9-22.	0.4	0